CFM
NKTR icon

Catalyst Funds Management’s Nektar Therapeutics NKTR Stock Holding History

Catalyst Funds Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482K Buy
+6,700
New +$381K 0.08% 253

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Catalyst Funds Management's NKTR Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 6,700 shares worth $482K. The stake represents 0.08% of the portfolio and ranks #253 among its holdings.

215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Catalyst Funds Management held 6,700 shares of Nektar Therapeutics worth $482K as of Q1 2026.
  • Nektar Therapeutics was a new Catalyst Funds Management position in Q1 2026.
  • Nektar Therapeutics made up 0.08% of Catalyst Funds Management's portfolio in Q1 2026, its #253 holding.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.